Kadimastem, Merck KGaA deal

Merck's Merck Serono S.A. division signed a memorandum of understanding to extend an April 2012 deal to use the Israeli company's drug-screening technology to discover oral therapies for multiple sclerosis (MS). A key goal of the MOU is to establish drug screening assays using stem cell-derived astrocytes (see BioCentury, May 7, 2012). ...